Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

Recent & Breaking News (TSX:ONC)

Advances in Treatments Are Leading to a Decline in Deaths from Cancer

Livemoney March 4, 2020

Realtor Credits New Immunotherapy for Destroying the Cancer That Threatened His Life

Livemoney March 2, 2020

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

Canada NewsWire February 28, 2020

Study Shows Surprisingly Low Number of Patients Seek Trials to Treat Cancer

Livemoney February 26, 2020

Agencies Expect Possible Treatments and Hope for a Coronavirus Vaccine as Soon as Three Months

Livemoney January 30, 2020

Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma

PR Newswire January 27, 2020

Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

PR Newswire January 22, 2020

Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

Canada NewsWire January 22, 2020

Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer

PR Newswire January 22, 2020

Some U.S. Airports Begin Checking Passengers for a Deadly New Chinese Virus

Livemoney January 21, 2020

'Guided-Missile' Cancer Drugs are the Biotech Sector's First Major Story of the 2020s

Livemoney January 15, 2020

New Medical device that is proving effective against the worlds toughest viruses, including: Ebola, Hep C, HIV, West Nile and Smallpox wins FDA designation "Breakthrough Device"

Livemoney January 15, 2020

Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma

PR Newswire January 13, 2020

Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma

PR Newswire January 9, 2020

Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

Accesswire December 12, 2019

Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology

Accesswire December 9, 2019

Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement

Accesswire December 6, 2019

Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue

Accesswire December 3, 2019

It's Been A Particularly Exciting Year For Biotech Stocks Across The Board

Livemoney November 26, 2019

Biotech Companies Focused On Cancer Research Are Being Acquired At Massive Valuations

Livemoney November 19, 2019